LifeMD Secures $50M Credit Facility and Adds $149-Monthly Wegovy Pill
LifeMD closed a senior secured revolving credit facility with Citizens Bank for up to $50 million ($30 million committed plus $20 million accordion) maturing Jan. 2, 2029, drawing no initial balance to fund organic growth. It began offering Novo Nordisk’s FDA-approved oral GLP-1 Wegovy pill at $149 monthly.
1. Closing of $50 Million Revolving Credit Facility
LifeMD announced on January 6, 2026, that it has closed a senior secured revolving credit facility with Citizens Bank, N.A., providing up to $50 million in liquidity. The facility includes $30 million of committed availability and an accordion feature allowing LifeMD to draw an additional $20 million through its January 2, 2029 maturity date. At closing, the company elected not to draw any funds, citing its current cash position and projected operating cash flow as sufficient to support planned organic growth initiatives. The absence of an upfront fee and competitively priced interest rates tied to Term SOFR (150–225 basis points spread) or the Alternate Base Rate (50–125 basis points spread) enhance LifeMD’s financial flexibility.
2. Financial Flexibility and Strategic Implications
By securing an undrawn credit line with tiered pricing and low commitment fees (0.225–0.30% on the unused portion), LifeMD strengthens its balance sheet without immediate dilution or cash interest burden. The facility can be deployed for potential mergers, acquisitions, or accelerated investment in its telehealth platform and proprietary compounding pharmacy. This enhanced liquidity provider optionality could support shareholder value creation through targeted bolt-on acquisitions or expanded marketing spend for patient acquisition in weight management, hormone therapy, and primary care segments.
3. Expansion of Virtual Weight Management Offering with Oral GLP-1 Therapy
On January 5, 2026, LifeMD broadened its collaboration with Novo Nordisk by integrating the newly FDA-approved Wegovy® oral semaglutide pill into its virtual care platform. Eligible patients can access all dosage levels—1.5mg and 4mg at $149 per month, rising to $199 and $299 for 4mg, 9mg and 25mg formulations after April 15—through LifeMD’s end-to-end telehealth service. The oral therapy follows a Phase 3 trial demonstrating an average 16.6% weight loss over 64 weeks versus 2.7% for placebo. LifeMD’s platform, which includes virtual visits, diagnostics, pharmacy fulfillment and real-time tracking, positions the company to capture a significant share of the emerging oral GLP-1 market and deepen its strategic partnership with Novo Nordisk.